News Releases

Dec 07, 2020
Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps
7500 mcg dose of LYR-210 achieved statistically significant improvement in a composite of the 4 cardinal symptoms of CRS at weeks 16 (p=0.021), 20 (p=0.012) and 24 (p=0.016) compared to control. 7500 mcg dose of LYR-210 achieved statistically significant improvement in SNOT-22 score at weeks 8
Additional Formats
Oct 28, 2020
Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors
WATERTOWN, Mass. --(BUSINESS WIRE)--Oct. 28, 2020-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)
Additional Formats
Displaying 1 - 10 of 20
Print Page
Email Alerts
RSS Feeds
Contact IR
Search
Back to Top